Current pharmacotherapy for testicular germ cell cancer

References

• Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol. 2003 Jul;170(1):5–11.
   PubMed Web of Science ®Google Scholar
• Park JS, Kim J, Elghiaty A, et al. Recent global trends in testicular cancer incidence and mortality. Medicine (Baltimore). 2018;97(37):e12390.
   PubMed Web of Science ®Google Scholar
• Hanna N, Einhorn LH. Testicular cancer: a reflection on 50 years of discovery. J Oncol. 2014 Oct 1; 32(28):3085–3092.
   Web of Science ®Google Scholar
• (IGCCCG) IGCCCG. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997;15(2):594–603.
   PubMed Web of Science ®Google Scholar
• Albers P, Albrecht W, Algaba F, et al. Guidelines on Testicular Cancer: 2015 Update. Eur Urol. 2015;68(6):1054–1068.
   PubMed Web of Science ®Google Scholar
• Boer H, Proost JH, Nuver J, et al. Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors. Ann Oncol. 2015;26(11):2305–2310.
   PubMed Web of Science ®Google Scholar
• Haugnes HS, Wethal T, Aass N, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010;28(30):4649–4657.
   PubMed Web of Science ®Google Scholar
• Chovanec M, Abu Zaif M, Hanna N, et al. Long-term toxicity of cisplatin in germ-cell tumor survivors. Ann Oncol. 2017;28(11):2670–2679.
   PubMed Web of Science ®Google Scholar
• Groot HJ, Lubberts S, de Wit R, et al. Risk of solid cancer after treatment of testicular Germ Cell Cancer in the Platinum Era. J Clin Oncol. 2018;36(24):2504–2513.
   PubMed Web of Science ®Google Scholar
• Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003;21(8):1513–1523.
   PubMed Web of Science ®Google Scholar
• Zagars GK, Ballo MT, Lee AK, et al. Mortality after cure of testicular seminoma. J Clin Oncol. 2004;22(4):640–647.
   PubMed Web of Science ®Google Scholar
• Horwich A, Fossa SD, Huddart R, et al. Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer. 2014;110(1):256–263.
   PubMed Web of Science ®Google Scholar
• Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Nat Canc Inst. 1997;89(19):1429–1439.
   PubMedGoogle Scholar
• Vehling S, Mehnert A, Hartmann M, et al. Anxiety and depression in long-term testicular germ cell tumor survivors. Gen Hosp Psychiatry. 2016;38:21–25.
   PubMed Web of Science ®Google Scholar
• Oechsle K, Hartmann M, Mehnert A, et al. Symptom burden in long-term germ cell tumor survivors. Support Care Cancer. 2016;24(5):2243–2250.
   PubMed Web of Science ®Google Scholar
• Horwich A, Shipley J, Huddart R. Testicular germ-cell cancer. Lancet. 2006;367(9512):754–765.
   PubMed Web of Science ®Google Scholar
• Kollmannsberger J, Tandstad T, Bedard PL, et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol. 2015;1(33):51–57.
   Google Scholar
• Mortensen MS, Lauritsen J, Gundgaard MG, et al. A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol. 2014 Dec;66(6):1172–1178.
   PubMed Web of Science ®Google Scholar
• Daugaard G, Gundgaard MG, Mortensen MS, et al. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. J Clin Oncol. 2014 1;32(34):3817–3823.
   PubMed Web of Science ®Google Scholar
• Boormans JL, Mayor de Castro J, Marconi L, et al. Testicular tumour size and rete testis invasion as prognostic factors for the risk of relapse of clinical stage i seminoma testis patientes unfer surveillance: a systematic review by the testicular cancer guidelines panel. Eur Urol. 2018;73(3):394–405.
   Web of Science ®Google Scholar
• Honecker F, Aparicio J, Berney D, et al. ESMO Consensus Conference on testicular germ cell cancer: diagnos,s treatment and follow-up. Ann Oncol. 2018 1;29(8):1658–1686.
   PubMed Web of Science ®Google Scholar
• Aparicio J, Germa JR, Garcia del Muro XG, et al. Risk-adapted management for patients with clinical stage I seminoma: the second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol. 2005 1;23(34):8717–8723.
   PubMed Web of Science ®Google Scholar
• Aparicio J, Maroto P, del Muro XG, et al. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol. 2011 10;29(35):4677–4681.
   PubMed Web of Science ®Google Scholar
• Jones WG, Fossa SD, Mead GM, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma: a report on medical research council trial TE18, European organisation for the research and treatment of cancer trial 30942 (ISRCT***N18525328). J Clin Oncol. 2005;23(6):1200–1208.
   PubMed Web of Science ®Google Scholar
• Oliver RT, Mead GM, Rustin GJ, et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol. 2011;29(8):957–962.
   PubMed Web of Science ®Google Scholar
• Powles T, Robinson D, Shamash J, et al. The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol. 2008;19(3):443–447.
   PubMed Web of Science ®Google Scholar
• Tandstad T, Stahl O, Dahl O, et al. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol. 2016;27(7):1299–1304.
   PubMed Web of Science ®Google Scholar
• Reiter WJ, Brodowicz T, Alavi S, et al. Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol. 2001;19(1):101–104.
   PubMed Web of Science ®Google Scholar
• Steiner H, Scheiber K, Berger AP, et al. Retrospective multicentre study of carboplatin monotherapy for clinical stage I seminoma. BJU Int. 2011;107(7):1074–1079.
   PubMed Web of Science ®Google Scholar
• Dieckmann KP, Dralle-Filiz I, Matthies C, et al. Testicular seminoma clinical stage 1: treatment-outcome on a routine care level. J Cancer Res Clin Oncol. 2016;142:1599–1607.
   PubMed Web of Science ®Google Scholar
• Read G, Stenning SP, Cullen MH, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol. 1992 Nov;10(11):1762–1768.
   PubMed Web of Science ®Google Scholar
• Albers P, Siener R, Kliesch S, et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Cln Oncol. 2003;21(8):1505–1512.
   PubMed Web of Science ®Google Scholar
• Vergouwe Y, Steyerberg EW, Eijkemans MJ, et al. Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J Clin Oncol. 2003;21(22):4092–4099.
   PubMed Web of Science ®Google Scholar
• Lago-Hernandez CA, Feldman H, O’Donnell E, et al. A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion. Ann Oncol. 2015;26(7):1396–1401.
   PubMed Web of Science ®Google Scholar
• Albers P, Siener R, Krege S, et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol. 2008;26(18):2966–2972.
   PubMed Web of Science ®Google Scholar
• Cullen MH, Stenning SP, Parkinson MC, et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol. 1996;14(4):1106–1113.
   PubMed Web of Science ®Google Scholar
• Pont J, Albrecht W, Postner G, et al. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol. 1996;14(2):441–448.
   PubMed Web of Science ®Google Scholar
• Chevreau C, Mazerolles C, Soulie M, et al. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol. 2004;46(2):209–14; discussion 14–5.
   PubMed Web of Science ®Google Scholar
• Tandstad T, Dahl O, Cohn-Cedermark G, et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol. 2009;27(13):2122–2128.
   PubMed Web of Science ®Google Scholar
• Tandstad T, Stahl O, Hakansson U, et al. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol. 2014;25(11):2167–2172.
   PubMed Web of Science ®Google Scholar
• Huddart RA, Reid AM. Adjuvant therapy for stage IB Germ Cell Tumors: one versus two cycles of BEP. Adv Urol. 2018 Apr 2;2018:8781698.
   PubMed Web of Science ®Google Scholar
• Huddart RA, Joffe JK, White JD, et al. A single Arm trial evaluating one cycle of BEP as adjuvant chemotherapy in high-risk, stage 1 non-seminomatous or combined germ cell tumors of the testis (NSGCTT). J Clin Oncol. 2017;35(6_suppl):400.
   Web of Science ®Google Scholar
• Oldenburg J, Aparicio J, Beyer J, et al. Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. Ann Oncol. 2015;26(5):833–838.
   PubMed Web of Science ®Google Scholar
• Nichols CR, Roth B, Albers P, et al. Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol. 2013;31:3490–3493.
   PubMed Web of Science ®Google Scholar
• Oing C, Seidel C, von Amsberg G, et al. Pharmacotherapeutic treatment of germ cell tumors: standardof care and recent developments. Exp Opin Pharmacother. 2016;17(4):545–6046.
   PubMed Web of Science ®Google Scholar
• Seidel C, Daugaard D, Tryakin A, et al. Intermediate prognosis in metastatic germ cell tumours- outcome and prognostic factors. Eur J Cancer. 2018;94:16–25.
   PubMed Web of Science ®Google Scholar
• Albany C, Adra N, Snavely AC, et al. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors. Ann Oncol. 2018 1;29(2):341–346.
   PubMed Web of Science ®Google Scholar
• Fankhauser CD, Sander S, Roth L, et al. Improved survival in metastatic germ-cell cancer. Ann Oncol. 2018 1;29(2):347–351.
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Kohrmann O, Tischer J, et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with „good-risk“ metastatic non-seminomatous germ cell tumors. Ann Oncol. 1996;7:1015–1021.
   PubMed Web of Science ®Google Scholar
• Horwich A, Sleijfer DT, Fossa SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a multiinstitutional medial research council/European organziation for research and treatment of cancer trial. J Clin Oncol. 1997;15(5):1844–1852.
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol. 1989;7(3):387–391.
   PubMed Web of Science ®Google Scholar
• Kondagunta GV, Bacik J, Bajorin D, et al. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol. 2005;23(36):9290–9294.
   PubMed Web of Science ®Google Scholar
• Culine S, Kerbrat P, Kramar A, et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol. 2007;18(5):917–924.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Delva R, Caty A, et al. A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study. Eur Urol. 2014;65(2):381–386.
   PubMed Web of Science ®Google Scholar
• Culine S, Theodore C, Terrier- Lacombe MJ, et al. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial. J Urol. 1997;157(3):855–858.
   PubMed Web of Science ®Google Scholar
• Troost MM, Sternberg N, de Wit R. Management of good risk germ-cell tumours. BJU Int. 2009;104(9):1387–1391.
   PubMedGoogle Scholar
• Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. New Engl J Med. 1987;316(23):1435–1440.
   PubMed Web of Science ®Google Scholar
• de Wit R, Stoter G, Sleijfer DT, et al. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer. 1998;78(6):828–832.
   PubMed Web of Science ®Google Scholar
• Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol. 1998;16(4):1287–1293.
   PubMed Web of Science ®Google Scholar
• de Wit R, Skoneczna I, Daugaard G, et al. Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. J Clin Oncol. 2012;30(8):792–799.
   PubMed Web of Science ®Google Scholar
• Feldman DR, Hu J, Dorff TB, et al. Paclitaxel, ifosfamide, and cisplatin efficacy for first-line treatment of patients with intermediate- or poor-risk germ cell tumors. J Clin Oncol. 2016;34(21):2478–2483.
   PubMed Web of Science ®Google Scholar
• Feldman DR, Hu J, Srivinas S, et al. Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT). J Clin Oncol. 2018;36(suppl):4508.
   Google Scholar
• Schmoll HJ, Kollmannsberger C, Metzner B, et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol. 2003;21:4083–4091.
   PubMed Web of Science ®Google Scholar
• Daugaard G, Skoneczna I, Aass N, et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol. 2011;22(5):1054–1061.
   PubMed Web of Science ®Google Scholar
• Huddart RA, Cafferty F, White J, et al. Long term follow-up of the MRC TE23 randomized phase II trial of intensive induction chemotherapy (CBOP/BEP) in poor prognosis germ cell tumours (GCT) (CRUK/05/014; ISRCTN53643604). Ann Oncol. 2018;29(8):165.
   Google Scholar
• Fizazi K, Pagliaro L, Laplanche A, et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol. 2014 Dec;15(13):1442–1450.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007;25(3):247–256.
   PubMed Web of Science ®Google Scholar
• Calabro F, Albers P, Bokemeyer C, et al. The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature. Eur Urol. 2012;61(6):1212–1221.
   PubMed Web of Science ®Google Scholar
• Oechsle K, Kollmannsberger C, Honecker F, et al. Cerebral metastases in non-seminomatous germ cell tumour patients undergoing primary high-dose chemotherapy. Eur J Cancer. 2008;44(12):1663–1669.
   PubMed Web of Science ®Google Scholar
• Feldman DR, Lorch A, Kramar A, et al. Brain metastases in patients with germ cell tumors: prognostic factors and treatment options – an analysis from the Global Germ Cell Caner Group. J Clin Oncol. 2016;34(4):345–351.
   PubMed Web of Science ®Google Scholar
• Oing C, Oechsle K, Necchi A, et al. Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study. Ann Oncol. 2017;28(3):576–58272.
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Nichols CR, Droz JP, et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol. 2002;20(7):1864–1873.
   PubMed Web of Science ®Google Scholar
• Tandstat T, Kollmannsberger CK, Roth BJ, et al. Practice makes perfect: the rest of the story in testicular cancer as a model curable neoplasm. J Clin Oncol. 2017;35(31):3525–3528.
   PubMed Web of Science ®Google Scholar
• Cathomas R, Klingbiel D, Bernard B, et al. Questioning the value of fluorodeoxyglucose positron emission tomography for residual lesions after chemotherapy for metastatic seminoma: results of an International Global Germ Cell Cancer Group Registry. J Clin Oncol. 2018;36(34):3381–3387.
   Web of Science ®Google Scholar
• International Prognostic Factors Study G, Lorch A, Beyer J, Bascoul-Mollevi C, et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol. 2010 20;28(33):4906–4911.
   PubMed Web of Science ®Google Scholar
• Berger LA, Bokemeyer C, Lorch A, et al. First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). J Cancer Res Oncol. 2014;140(7):1211–1220.
   PubMed Web of Science ®Google Scholar
• Lorch A, Bascoul-Mollevi C, Kramar A, et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol. 2011 1;29(16):2178–2184.
   PubMed Web of Science ®Google Scholar
• Loehrer PJ Sr., Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol. 1998;16(7):2500–2504.
   PubMed Web of Science ®Google Scholar
• McCaffrey JA, Mazumdar M, Bajorin DF, et al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol. 1997;15(7):2559–2563.
   PubMed Web of Science ®Google Scholar
• Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol. 2005;23(27):6549–6555.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Gravis G, Flechon A, et al. Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial. Ann Oncol. 2014;25(5):987–991.
   PubMed Web of Science ®Google Scholar
• Oing C, Lorch A. The role of salvage high-dose chemotherapy in relapsed male germ cell tumors. Oncol Rest Treat. 2018;41(6):365–369.
   PubMed Web of Science ®Google Scholar
• Nichols CR, Tricot G, Williams SD, et al. Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol. 1989;7(7):932–939.
   PubMed Web of Science ®Google Scholar
• Adra N, Abonour R, Althouse SK. High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed germ cell tumors: the Indiana university experience. J Clin Oncol. 2017 1;35(10):1096–1102.
   PubMed Web of Science ®Google Scholar
• Feldman DR, Sheinfeld J, Bajorin DF, et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol. 2010 1;28(10):1706–1713.
   PubMed Web of Science ®Google Scholar
• Kondagunta GV, Bacik J, Sheinfeld J, et al. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol. 2007;25(1):85–90.
   PubMed Web of Science ®Google Scholar
• Pico JL, Rosti G, Kramar A, et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol. 2005;16(7):1152–1159.
   PubMed Web of Science ®Google Scholar
• Lorch A, Kleinhans A, Kramar A, et al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol. 2012;30(8):800–805.
   PubMed Web of Science ®Google Scholar
• Feldman DR, Huddart R, Hall E, et al. Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER Trial. J Cancer. 2011;2:374–377.
   PubMed Web of Science ®Google Scholar
• Hartmann JT, Schmoll HJ, Kuczyk MA, et al. Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. Ann Oncol. 1997;8(6):531–538.
   PubMed Web of Science ®Google Scholar
• Fox EP, Weathers TD, Williams SD, et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol. 1993;11(7):1294–1299.
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Oechsle K, Honecker F, et al. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol. 2008;19(3):448–453.
   PubMed Web of Science ®Google Scholar
• Beyer J, Kramar A, Mandanas R, et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol. 1996;14(10):2638–2645.
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy MJ, Feldman DR, Carver BS, et al. Late relapse of testicular germ cell tumors. Urol Clin North Am. 2015 Aug;42(3):359–368.
   PubMed Web of Science ®Google Scholar
• Veenstra CM, Vaughn DJ. Third-line chemotherapy and novel agents for metastatic germ cell tumors. Hematol Oncol Clin North Am. 2011;25(3):577–91, ix.
   PubMed Web of Science ®Google Scholar
• O’Carrigan B, Grimison P. Current chemotherapeutic approaches for recurrent or refractory germ cell tumors. Urol Oncol. 2015;33(8):343–354.
   PubMed Web of Science ®Google Scholar
• Gerwing M, Jacobsen C, Dyshlovoy S, et al. Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells. J Cancer Res Clin Oncol. 2016;142(9):1979–1990.
   PubMed Web of Science ®Google Scholar
• Oechsle K, Kollmannsberger C, Honecker F, et al. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. Eur Urol. 2011 Oct;60(4):850–855.
   PubMed Web of Science ®Google Scholar
• Sadeghi S, Quinn D, Tsao-Wei D, et al. Phase II study of gemcitabine, oxaliplatin, and paclitaxel (GOT) on a 2-weekly schedule in patients (pts) with refractory germ cell tumor (rGCT): final results. J Clin Oncol. 2013;31:4531.
   Web of Science ®Google Scholar
• Seidel C, Oechsle K, Lorch A, et al. Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group. Urol Oncol. 2016;34(4):167.e21-8.
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Brames MJ, Juliar B, et al. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol. 2007;25(5):513–516.
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Beyer J, Liersch R, et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol. 2004 1;22(1):108–114.
   PubMed Web of Science ®Google Scholar
• Pectasides D, Pectasides M, Farmakis D, et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol. 2004 Mar;15(3):493–497.
   PubMed Web of Science ®Google Scholar
• De Giorgi U, Rosti G, Aieta M, et al. Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor. Eur Urol. 2006 Nov;50(5):1032–8; discussion 38–9.
   PubMed Web of Science ®Google Scholar
• Pectasides D, Pectasides M, Farmakis D, et al. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study. Eur Urol. 2004;46(2):216–221.
   PubMed Web of Science ®Google Scholar
• Shamash J, Powles T, Mutsvangwa K, et al. A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours. Ann Oncol. 2007;18(5):925–930.
   PubMed Web of Science ®Google Scholar
• Necchi A, Nicolai N, Mariani L, et al. Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes. Clin Genitourin Cancer. 2014;12(1):63–69.e1.
   PubMed Web of Science ®Google Scholar
• Raggi D, Giannatempo P, Miceli R, et al. Etoposide, methotrexate, and dactinomycin alternating with cyclophosphamide and vincristine (EMA/CO) for males with HCG-expressing, chemoresistant germ cell tumors. Am J Clin Oncol. 2017;40(1):60–65.
   PubMed Web of Science ®Google Scholar
• Bagrodia A, Lee BH, Lee W, et al. Genetic determinants of cisplatin resistance in patients with advanced germ cell tumors. J Clin Oncol. 2016;34(33):4000–4007.
   PubMed Web of Science ®Google Scholar
• Necchi A, Bratslavsky G, Corona RJ, et al. Genomic characterization of testicular germ cell tumors relapsing after chemotherapy. Eur Urol Focus. 2018 Jul 16. pii: S2405-4569(18)30179–2.
   Google Scholar
• Oing C, Kollmannsberger C, Oechsle K, et al. Investigational targeted therapies for the treatment of testicular germ cell tumors. Exp Opin Invest Drugs. 2016;25(9):1033–1043.
   PubMed Web of Science ®Google Scholar
• Schmidtova S, Kalavska K, Kucerova L. Molecular mechanisms of cisplatin chemoresistance and its circumventing in testicular germ cell tumors. Curr Oncol Rep. 2018;20(11):88.
   PubMed Web of Science ®Google Scholar
• Chieffi P, Chieffi S. Molecular biomarkers as potential targets for therapeutic strategies in human testicular germ cell tumors: an overview. J Cell Physiol. 2013;228(8):1641–1646.
   PubMed Web of Science ®Google Scholar
• Nitzsche B, Gloesenkamp C, Schrader M, et al. Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer. Br J Cancer. 2012 Nov 20;107(11):1853–1863.
   PubMed Web of Science ®Google Scholar
• Juliachs M, Munoz C, Moutinho CA, et al. The PDGFRbeta-AKT pathway contributes to CDDP-acquired resistance in testicular germ cell tumors. Clin Canc Res. 2014 1;20(3):658–667.
   PubMed Web of Science ®Google Scholar
• Feldman DR, Turkula S, Ginsberg MS, et al. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Invest New Drugs. 2010;28(4):523–528.
   PubMed Web of Science ®Google Scholar
• Skoneczna IA, Natorska U, Tacikowska M, et al. Sorafenib monotherapy in patients with inoperable/recurrent germ cell tumors (GCT) refractory to chemotherapy: phase II study. J Clin Oncol. 2014;32(suppl4):abstr 367.
   Google Scholar
• Feldman DR, Einhorn LH, Quinn DI, et al. A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. Invest New Drugs. 2013;31(4):1016–1022.
   PubMed Web of Science ®Google Scholar
• Rick O, Braun T, Siegert W, et al. Activity of thalidomide in patients with platinum-refractory germ-cell tumours. Eur J Cancer. 2006;42(12):1775–9116.
   PubMed Web of Science ®Google Scholar
• Necchi A, Lo Vullo S, Giannatempo P, et al. Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial. Ann Oncol. 2017 1;28(6):1346–1351.
   PubMed Web of Science ®Google Scholar
• Oechsle K, Honecker F, Cheng T, et al. Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study. Ann Oncol. 2011;22(12):2654–2660.
   PubMed Web of Science ®Google Scholar
• Fenner M, Oing C, Dieing A, et al. Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group. J Cancer Res Clin Oncol. 2019 Mar;145(3):717–723.
   PubMed Web of Science ®Google Scholar
• Mego M, Svetlovska D, Miskovska V, et al. Phase II study of everolimus in refractory testicular germ cell tumors. Urol Oncol. 2016;34(3):122.e17-22.
   PubMed Web of Science ®Google Scholar
• Frankhauser CD, Fontecedro AC, Beyer J, et al. Frequent expression of PD-L1 in testicular germ cell tumors. Br J Cancer. 2015;113(3):411–3118.
   PubMed Web of Science ®Google Scholar
• Cierna Z, Mego M, Miskovska V, et al. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors. Ann Oncol. 2016;27(2):300–305.
   PubMed Web of Science ®Google Scholar
• Honecker F, Wermann H, Mayer F, et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol. 2009;27(13):2129–2136.
   PubMed Web of Science ®Google Scholar
• Shen H, Shih J, Hollem DP, et al. Integrated molecular characterization of testicular germ cell tumors. Cell Rep. 2018;23:3392–3406.
   PubMed Web of Science ®Google Scholar
• Yarchoan M, Hopkins A, Jaffe EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. New Engl J Med. 2017;377(25):2500–2501.
   PubMed Web of Science ®Google Scholar
• Adra N, Einhorn LH, Althouse SK, et al. Phase II trial of pembrolizumab in patients with platinum refractory germ cell tumors: a Hoosier Cancer Research Network Study GU14-206. Ann Oncol. 2018;29:209–214.
   PubMed Web of Science ®Google Scholar
• Necchi A, Giannatempo R, Raggi D, et al. An open-label randomized phase 2 study of durvalumab alone or in combination with tremelimumab in patients with advanced germ cell tumors (APACHE): results from the first planned interim analysis. Eur Urol. 2019 Jan;75(1):201–203.
   Web of Science ®Google Scholar
• Schönberger S, van Beekum C, Götz B, et al. Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines. J Cell Mol Med. 2018;22(1):568–575.
   PubMed Web of Science ®Google Scholar
• Necchi A, Anichini R, Raggi D, et al. Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors after chemotherapy Failure. Clin Genitourin Cancer. 2016;14:261–264.
   PubMed Web of Science ®Google Scholar
• Albany C, Einhorn L, Garbo L, et al. Treatment of CD30-expressing germ cell tumors and sex cord stromal tumors with brentuximab vedotin: identification and report of seven cases. Oncologist. 2018 Mar;23(3):316–323.
   PubMed Web of Science ®Google Scholar
• Albany C, Hever-Jardine MP, von Herrmann KM, et al. Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine. Oncotarget. 2017;8(2):2949–2959.
   PubMedGoogle Scholar
• Matei D, Ghamande S, Roman L, et al. A phase i clinical trial of guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer: clinical, pharmacokinetic, and pharmacodynamic analyses. Clin Canc Res. 2018;24(10):2285–2293.
   PubMed Web of Science ®Google Scholar
• Cavallo F, Graziani G, Antinozzi C, et al. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition. PLoS One. 2012;7:e51563.
   PubMed Web of Science ®Google Scholar
• Nieto Y, Tu SM, Bassett R, et al. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. Ann Oncol. 2015;26(10):2125–2132.
   PubMed Web of Science ®Google Scholar
• Nieto Y, Tu SM, Campbell MT, et al. Infusional gemcitabine + docetaxel/melphalan/carboplatin (GemDMC) ± bevacizumab (BEV) as an effective high-dose chemotherapy (HDC) regimen for refractory of poor-risk relapsed germ-cell tumors (GCT). J Clin Oncol. 2017;35(15):4519.
   Google Scholar